Not investment advice. Origin reports data from public SEC filings with cryptographic provenance. No buy/sell/hold recommendations. Past performance does not indicate future results.
## Tempest Therapeutics: Incremental Price Erosion Continues With No New Catalysts to Anchor
Since the inaugural observation on October 13, 2026, TPST has shed an additional $0.0614 per share, moving from $0.7427 to $0.6813 — a roughly 8.3% decline in a single session with no apparent catalyst captured in the data. The filing signal profile remains unchanged (risk_factor clusters at 81, 76, and 75; strategic_event clusters at 75, 59, 59, 58, and 57), and the AI query count has only ticked up by 3 to 265 all-time, suggesting this price move is not drawing meaningful new investor attention on Origin. Transcript capture remains at zero, leaving management's voice entirely absent from the analytical record. The continued absence of any conference call or presentation transcript is increasingly notable. At $0.68 and with no earnings color on record, the market is pricing TPST almost purely on filing disclosures and secondary signals. The dense strategic_event cluster in the 10-K — five separate high-match signals — implies documented corporate activity that has not yet been translated into narrative for investors. Whether those signals reflect partnership discussions, asset-level decisions around TPST-1120 or TPST-1495, or capital structure events remains unresolved. The key watch items established at inception remain active: cash runway disclosure relative to burn rate is now more pressing given the price decline, as equity financing at these levels would be highly dilutive. Any clinical readout, partnership announcement, or conference appearance that generates a transcript capture would represent the first meaningful narrative data point in this coverage.
## Tempest Therapeutics Enters Coverage: Clinical-Stage Oncology Name Trading Near Cash Floor
This is the inaugural observation for TPST, establishing a baseline as of October 12, 2026, with shares at $0.7427 and market capitalization effectively below $1B classification — likely sub-$50M given the stock price and typical share count for a company of this profile. The 10-K filing reveals a notably dense risk environment: 81, 76, and 75 matches on risk factor signals, alongside a cluster of strategic event signals (75, 59, 59, 58, 57 matches), suggesting the filing contains meaningful disclosure around pipeline decisions, partnership activity, or capital structure events worth parsing carefully. The 262 all-time AI queries on Origin indicate moderate investor curiosity despite zero transcript captures, meaning conference call color is entirely absent from the analytical record so far. The absence of earnings transcripts is a meaningful gap. For a clinical-stage oncology company trading under $1, narrative from management — around cash runway, trial milestones, and partnership strategy — is often more market-moving than any single data point. The high strategic event signal count in the 10-K suggests Tempest has documented significant corporate activity, potentially including collaborations or asset-level decisions, that warrants close reading. Key items to watch: any clinical readout for their TPST-1120 (PPARα antagonist) or TPST-1495 programs, cash runway disclosure relative to current burn rate, and whether a transcript from an upcoming earnings call or conference appearance gets captured. The next observation should anchor to one of those catalysts.